Repligen (NASDAQ:RGEN) reported Q1 EPS of $0.92, $0.20 better than the analyst estimate of $0.72. Revenue for the quarter came in at $206.4 million versus the consensus estimate of $185.48 million.
GUIDANCE:
Repligen sees FY2022 EPS of $3.07-$3.15, versus the consensus of $3.25. Repligen sees FY2022 revenue of $770-800 million, versus the consensus of $819.5 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.